esophageal cancer. Malignant neoplasm of esophagus, unspecified
Conditions
Interventions
Intervention group: Received 3 to 5 courses of weekly induction chemotherapy with paclitaxel (50 mg / m2) and carboplatin (AUC 2) followed by hypofractionated radiotherapy with a total dose of 40 Gy a
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: carcinoma in thoracic or abdominal esophagus performance status above or equal to 70% in karnofsky criteria or less or equal to 1 in ECOG criteria presence of 3rd grade or more dysphasia or disease in T2-T4 N0 M0 or any T N+ M0 stage consent to the whole treatment program including surgery
Exclusion criteria
Exclusion criteria: presence of metastatic disease presence of cervical esophagus invasion to heart, trachea, bronchus or aorta dissent to surgery history of cancer or other diseases that interfere to complete the treatment program
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of pathological response based on tumor necrosis in microscopic examination. Timepoint: 4 weeks after completion of neoadjuvant chemoradiotherapy. Method of measurement: Pathological evaluation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Scale of dysphagia. Timepoint: before the intervention and after completing treatment. Method of measurement: dysphagia severity scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShervin Mashreghi Moghaddam
Mashhad University of Medical Sciences
Outcome results
None listed